Researchers at the Medical University of Vienna have uncovered how a little-studied protein, TRAT1 (T Cell Receptor ...

Researchers at the Medical University of Vienna have taken a closer look at a previously largely unknown component of the ...

Researchers at the Medical University of Vienna have taken a closer look at a previously largely unknown component of the ...

Pilatus Biosciences Announces Issuance of Foundational Global Patent Covering Novel CD36-Targeted Immunotherapy ...

Samer A. Srour, MB ChB, MS, has long hoped the remarkable success of chimeric antigen receptor therapy for treatment of hematologic malignancies could be replicated in other cancer types.“There is a ...

Preclinical data support Abalos’ first-in-class approach of safely harnessing the immunostimulatory and anti-tumoral properties of arenaviruses to treat solid tumors -- Düsseldorf, Germany, October 14 ...

CRISPR-based tools can’t easily access the DNA in these organelles, but researchers are finding other ways in.

Sana Biotechnology, Inc. is a Strong Buy with promising cell therapies for diabetes & B-cell disorders. Click here to find ...

T-cell engagers, especially BiTEs, show promise in treating solid tumors by targeting tumor-associated antigens and redirecting T-cell activity. Tarlatamab, targeting DLL3 in SCLC, demonstrated ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between September ...

ORR and 79% DCR observed in heavily pretreated TMB-H or MSI-H/dMMR tumors across six major solid tumor types, including colorectal, lung, breast, ...